actinium-225 cyclodextrin nanocarrier

Actinium-225 cyclodextrin nanocarrier is an experimental targeted alpha therapy (TAT) being developed for the treatment of glioblastoma multiforme (GBM). It utilizes a supramolecular cyclodextrin-based nanopolymer to sequester actinium-225 (Ac-225). This architecture is specifically designed to address the "recoil" problem inherent in Ac-225 decay, where radioactive daughter nuclides (such as francium-221 and bismuth-213) escape conventional chelators and cause systemic toxicity, particularly in the kidneys. The nanocarrier provides a secondary containment barrier to retain these progeny while delivering high-linear energy transfer (LET) alpha radiation to induce lethal DNA double-strand breaks in cancer cells. Developed by researchers at Ayudarea, it has shown potent cytotoxicity in patient-derived glioblastoma stem cells and remains effective in hypoxic tumor environments.

Other names

actinium-225 cyclodextrin nanopolymeractinium225 cyclodextrin nanopolymeractinium 225 cyclodextrin nanopolymercyclodextrin-based supramolecular nanocarrier